Celltrion CCO On The Big US Build-Up, Direct Sales Model
Executive Summary
Celltrion USA’s chief commercial officer Thomas Nusbickel tells Scrip how he’s shaping the South Korean group’s operations ahead of key launches that include assets in the immunology segment. He also weighs in on whether big pharma will stay in the biosimilars game over the long term.
You may also be interested in...
Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.
Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.
Sun Pharma Chief: We Are Not 'All In' In Biologics
Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.